Compounds > naltrexone

naltrexone and sumatriptan

naltrexone has been researched along with sumatriptan in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (36.36)	29.6817
2010's	6 (54.55)	24.3611
2020's	1 (9.09)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Brockmöller, J; Friesacher, HR; Meyer, MJ; Neumann, VE; Tzvetkov, MV; Zdrazil, B	1
Afshari, K; Daneshpazhooh, M; Dehpour, AR; Foroutan, A; Haddadi, NS; Ostadhadi, S; Shakiba, S	1
Amanlou, A; Dehpour, AR; Ejtemaei-Mehr, S; Eslami, F; Ghasemi, M; Rahimi, N; Rashidian, A; Shayan, M; Solaimanian, S	1

Reviews

1 review(s) available for naltrexone and sumatriptan

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

10 other study(ies) available for naltrexone and sumatriptan

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations	2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. Journal of medicinal chemistry, 2019, 11-14, Volume: 62, Issue:21 Topics: Analgesics, Opioid; HEK293 Cells; Humans; Inhibitory Concentration 50; Models, Molecular; Organic Cation Transporter 1; Permeability; Protein Conformation	2019
Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids. Archives of dermatological research, 2018, Volume: 310, Issue:2 Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Humans; Injections, Intradermal; Male; Mice; Naltrexone; Narcotic Antagonists; Opioid Peptides; Oxadiazoles; Piperazines; Pruritus; Quaternary Ammonium Compounds; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Sumatriptan	2018
Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K Toxicology and applied pharmacology, 2022, 11-01, Volume: 454 Topics: Adenosine Triphosphate; Animals; Anticonvulsants; bcl-2-Associated X Protein; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Glyburide; Mice; Models, Theoretical; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Pentylenetetrazole; Piperidines; Potassium Channel Blockers; Potassium Channels; Pyridines; Receptors, Opioid; Seizures; Stroke; Sumatriptan; Tumor Necrosis Factor-alpha	2022